Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity: 2012-2024

Historic Liabilities and Shareholders Equity for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $1.7 billion.

  • Agios Pharmaceuticals' Liabilities and Shareholders Equity fell 22.66% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 39.62%. This contributed to the annual value of $1.7 billion for FY2024, which is 77.48% up from last year.
  • Agios Pharmaceuticals' Liabilities and Shareholders Equity amounted to $1.7 billion in FY2024, which was up 77.48% from $937.1 million recorded in FY2023.
  • Agios Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.7 billion during FY2024, with a 5-year trough of $853.0 million in FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.3 billion, with a median of $1.2 billion in 2022.
  • In the last 5 years, Agios Pharmaceuticals' Liabilities and Shareholders Equity fell by 24.35% in 2023 and then spiked by 77.48% in 2024.
  • Agios Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $853.0 million in 2020, then surged by 68.56% to $1.4 billion in 2021, then decreased by 13.84% to $1.2 billion in 2022, then declined by 24.35% to $937.1 million in 2023, then spiked by 77.48% to $1.7 billion in 2024.